{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:35:35Z","timestamp":1745469335320,"version":"3.40.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In response to the COVID-19 pandemic, a collaborative public\u2013private partnership was launched to harness evidence from rapidly accruing real-world data (RWD) in various healthcare settings, with the goal of characterizing and understanding COVID-19 in near real-time, by applying rigorous epidemiological methods and defining research best practices. Projects were conducted in 4 phases: Research Planning and Prioritization, Protocol Development, Protocol Implementation, and Results Dissemination. During these projects, areas were identified with a current or future need to enhance existing best practices. This report provides a summary of our research processes, including application of new and existing practices, along with key learnings related to the challenges of conducting research when the clinical landscape is rapidly evolving as was the case during the first year of the COVID-19 pandemic. Such processes and learnings may be helpful to the broader research community when using RWD to understand or address\u00a0future public health priorities.<\/jats:p>","DOI":"10.1007\/s43441-025-00748-4","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:05:23Z","timestamp":1742317523000},"page":"629-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Increasing the Utility of Real-World Data to Inform Public Health Decision Making Through a US-based Private\u2013Public Partnership: 10 Lessons Learned from a Principled Approach to Rapid Pandemic RWE Generation"],"prefix":"10.1007","volume":"59","author":[{"given":"Nicolle M.","family":"Gatto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Garry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00e9vine","family":"Zariffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aloka","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"20","key":"748_CR1","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1001\/jama.2022.4877","volume":"327","author":"MC Bradley","year":"2022","unstructured":"Bradley MC, Perez-Vilar S, Chillarige Y, Dong D, Martinez AI, Weckstein AR, Dal Pan GJ. Systemic corticosteroid use for COVID-19 in US outpatient settings from April 2020 to August 2021. JAMA. 2022;327(20):2015\u20138. https:\/\/doi.org\/10.1001\/jama.2022.4877.","journal-title":"JAMA"},{"issue":"1","key":"748_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","volume":"181","author":"S Gupta","year":"2021","unstructured":"Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, Reiser J. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41\u201351.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"748_CR3","doi-asserted-by":"publisher","first-page":"e0271574","DOI":"10.1371\/journal.pone.0271574","volume":"17","author":"CT Bramante","year":"2022","unstructured":"Bramante CT, Johnson SG, Garcia V, Evans MD, Harper J, Wilkins KJ, Huling JD, Mehta H, Alexander C, Tronieri J, Hong S, Kahkoska A, Alamgir J, Koraishy F, Hartman K, Yang K, Abrahamsen T, St\u00fcrmer T, Buse JB. Diabetes medications and associations with Covid-19 outcomes in the N3C database: a national retrospective cohort study. PLoS ONE. 2022;17(11):e0271574. https:\/\/doi.org\/10.1371\/journal.pone.0271574.","journal-title":"PLoS ONE"},{"issue":"06","key":"748_CR4","doi-asserted-by":"publisher","first-page":"22280795","DOI":"10.1101\/2022.10.06.22280795","volume":"10","author":"MD Brannock","year":"2022","unstructured":"Brannock MD, Chew RF, Preiss AJ, Hadley EC, McMurry JA, Leese PJ, Girvin AT, Crosskey M, Zhou AG, Moffitt RA, Funk MJ, Pfaff ER, Haendel MA, Chute CG, N3C and RECOVER Consortia. Long COVID risk and Pre-COVID vaccination: an EHR-based cohort study from the RECOVER program. Medrxiv. 2022;10(06):22280795. https:\/\/doi.org\/10.1101\/2022.10.06.22280795.","journal-title":"Medrxiv."},{"issue":"11","key":"748_CR5","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2337\/dc22-0730","volume":"45","author":"R Wong","year":"2022","unstructured":"Wong R, Vaddavalli R, Hall MA, Patel MV, Bramante CT, Casarighi E, Johnson SG, Lingam V, Miller JD, Reusch J, Saltz M, St\u00fcrmer T, Tronieri JS, Wilkins KJ, Buse JB, Saltz J, Huling JD, Moffitt R. N3C consortium: effect of SARS-CoV-2 infection and infection severity on longer-term glycemic control and weight in people with type 2 diabetes. Diabetes Care. 2022;45(11):2709\u201317. https:\/\/doi.org\/10.2337\/dc22-0730.","journal-title":"Diabetes Care"},{"issue":"5","key":"748_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2337\/dc21-2186","volume":"45","author":"R Wong","year":"2022","unstructured":"Wong R, Hall M, Vaddavalli R, Anand A, Arora N, Bramante CT, Garcia V, Johnson S, Saltz M, Tronieri JS, Yoo YJ, Buse JB, Saltz J, Miller J, Moffitt R, N3C Consortium. Glycemic control and clinical outcomes in us patients with COVID-19: data from the national COVID cohort collaborative (N3C) database. Diabetes Care. 2022;45(5):1099\u2013106. https:\/\/doi.org\/10.2337\/dc21-2186.","journal-title":"Diabetes Care"},{"issue":"7","key":"748_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2337\/dc21-0065","volume":"44","author":"AR Kahkoska","year":"2021","unstructured":"Kahkoska AR, Abrahamsen TJ, Alexander GC, Bennett TD, Chute CG, Haendel MA, Klein KR, Mehta H, Miller JD, Moffitt RA, St\u00fcrmer T, Kvist K, Buse JB. Association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 outcomes. Diabetes Care. 2021;44(7):1564\u201372. https:\/\/doi.org\/10.2337\/dc21-0065.","journal-title":"Diabetes Care"},{"key":"748_CR8","unstructured":"https:\/\/evidenceaccelerator.org\/covid-19-real-world-evidence-primer"},{"issue":"4","key":"748_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/cpt.2185","volume":"109","author":"JM Franklin","year":"2021","unstructured":"Franklin JM, Lin KJ, Gatto NM, et al. Real-world evidence for assessing pharmaceutical treatments in the context of COVID-19. Clin Pharmacol Ther. 2021;109(4):816\u201328.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"748_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12874-023-01839-2","volume":"23","author":"H Sidky","year":"2023","unstructured":"Sidky H, Young JC, Girvin AT, Lee E, Shao YR, Hotaling N, Michael S, Wilkins KJ, Setoguchi S, Funk MJ, N3C Consortium. Data quality considerations for evaluating COVID-19 treatments using real world data: learnings from the National COVID Cohort Collaborative (N3C). BMC Med Res Methodol. 2023;23(1):46. https:\/\/doi.org\/10.1186\/s12874-023-01839-2.","journal-title":"BMC Med Res Methodol"},{"key":"748_CR11","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.jbi.2023.104295","volume":"139","author":"E Casiraghi","year":"2023","unstructured":"Casiraghi E, Wong R, Hall M, Coleman B, Notaro M, Evans MD, Tronieri JS, Blau H, Laraway B, Callahan TJ, Chan LE, Bramante CT, Buse JB, Moffitt RA, St\u00fcrmer T, Johnson SG, Raymond Shao Y, Reese J, Robinson PN, Paccanaro A, Valentini G, Huling JD, Wilkins KJ. A method for comparing multiple imputation techniques: a case study on the US national COVID cohort collaborative. J Biomed Inform. 2023;139:104295. https:\/\/doi.org\/10.1016\/j.jbi.2023.104295.","journal-title":"J Biomed Inform"},{"issue":"6","key":"748_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/cpt.512","volume":"100","author":"S Schneeweiss","year":"2016","unstructured":"Schneeweiss S, Eichler HG, Garcia-Altes A, et al. Real world data in adaptive biomedical innovation: a framework for generating evidence fit for decision-making. Clin Pharmacol Ther. 2016;100(6):633\u201346.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"748_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/cpt.316","volume":"99","author":"S Schneeweiss","year":"2016","unstructured":"Schneeweiss S. Improving therapeutic effectiveness and safety through big healthcare data. Clin Pharmacol Ther. 2016;99(3):262\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"748_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cpt.1480","volume":"106","author":"NM Gatto","year":"2019","unstructured":"Gatto NM, Reynolds RF, Campbell UB. A structured preapproval and postapproval comparative study design framework to generate valid and transparent real-world evidence for regulatory decisions. Clin Pharmacol Ther. 2019;106(1):103\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"748_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cpt.2466","volume":"111","author":"NM Gatto","year":"2021","unstructured":"Gatto NM, Campbell UB, Rubinstein E, et al. The structured process to identify fit-for-purpose data: a data feasibility assessment framework. Clin Pharmacol Ther. 2021;111(1):122\u201334.","journal-title":"Clin Pharmacol Ther"},{"issue":"372","key":"748_CR16","doi-asserted-by":"publisher","first-page":"m4856","DOI":"10.1136\/bmj.m4856","volume":"12","author":"SV Wang","year":"2021","unstructured":"Wang SV, Pinheiro S, Hua W, et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;12(372):m4856.","journal-title":"BMJ"},{"issue":"3","key":"748_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.329","volume":"99","author":"SV Wang","year":"2016","unstructured":"Wang SV, Verpillat P, Rassen JA, Patrick A, Garry EM, Bartels DB. Transparency and reproducibility of published analyses of cohort studies in healthcare databases. Clin Pharmacol Ther. 2016;99(3):325\u201332.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR18","unstructured":"United States Food and Drug Administration (FDA). Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision Making for Drug and Biological Products. Draft Guidance for Industry. [Internet]. United States Food and Drug Administration (FDA); 2021 [cited 2022 May 6]. Available from: https:\/\/www.fda.gov\/media\/152503\/download"},{"key":"748_CR19","unstructured":"https:\/\/evidenceaccelerator.org\/"},{"key":"748_CR20","unstructured":"https:\/\/healthverity.com\/covid-19-masterset\/"},{"issue":"9","key":"748_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267815","volume":"17","author":"SE Vititoe","year":"2022","unstructured":"Vititoe SE, Easthausen IJ, Lasky T, Chakravarty A, Bradley MC, Roe LM, Gatto NM, Weckstein AR, Garry EM. Describing characteristics and treatment patterns of patients hospitalized with COVID-19 by race and ethnicity in a national RWD during the early months of the pandemic. PLoS ONE. 2022;17(9): e0267815. https:\/\/doi.org\/10.1371\/journal.pone.0267815.","journal-title":"PLoS ONE"},{"issue":"7","key":"748_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/pds.5436","volume":"31","author":"EM Garry","year":"2022","unstructured":"Garry EM, Weckstein AR, Quinto K, et al. Categorization of COVID-19 severity to determine mortality risk. Pharmacoepidemiol Drug Saf. 2022;31(7):721\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"748_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4212\/cjhp.v67i1.1320","volume":"67","author":"MP Tully","year":"2014","unstructured":"Tully MP. Research: articulating questions, generating hypotheses, and choosing study designs. Can J Hosp Pharm. 2014;67(1):31\u20134.","journal-title":"Can J Hosp Pharm"},{"key":"748_CR24","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacy. ENCePP Guide on Methodological Standards in Pharmacoepidemiology [Internet]. 2022 [cited 2022 Jan 21]. https:\/\/www.encepp.eu\/standards_and_guidances\/methodologicalGuide.shtml"},{"key":"748_CR25","unstructured":"Gatto N. Effect of Dexamethasone on Inpatient Mortality Among Hospitalized COVID-19 Patients [Internet]. clinicaltrials.gov; 2022 Dec [cited 2022 Feb 11]. Report No.: NCT04926571. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04926571"},{"issue":"8","key":"748_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"79","key":"748_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"1","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;1(79):70\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"748_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00001648-199901000-00008","volume":"10","author":"S Greenland","year":"1999","unstructured":"Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37.","journal-title":"Epidemiology"},{"issue":"2","key":"748_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/aje\/155.2.176","volume":"155","author":"MA Hern\u00e1n","year":"2002","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S, Werler MM, et al. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002;155(2):176\u201384.","journal-title":"Am J Epidemiol"},{"key":"748_CR30","unstructured":"Daniel G, Silcox C, Bryan J, et al. Characterizing RWD quality and relevancy for regulatory purposes. Duke-Margolis Center for Health Policy; 2018 [cited 2022 Feb 11]. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2020-03\/characterizing_rwd.pdf"},{"key":"748_CR31","unstructured":"Mahendraratnam N, Silcox C, Mercon K, et al. Determining real-world data\u2019s fitness for use and the role of reliability. Duke-Margolis Center for Health Policy; 2019 [cited 2022 Feb 11]. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2019-11\/rwd_reliability.pdf"},{"key":"748_CR32","unstructured":"Reagan-Udall Foundation for the Food and Drug Administration. COVID-19 Real-World Evidence Primer. Reagan-Udall Foundation for the Food and Drug Administration; 2022 [cited 2022 Feb 11]. https:\/\/evidenceaccelerator.org\/sites\/default\/files\/2022-09\/COVID-19%20Real-World%20Evidence%20Primer%20v8.pdf"},{"key":"748_CR33","unstructured":"United States Food and Drug Administration (FDA). Framework for FDA\u2019s Real-World Evidence Program. United States Food and Drug Administration (FDA); 2018 [cited 2022 Feb 11]. https:\/\/www.fda.gov\/media\/120060\/download"},{"issue":"6","key":"748_CR34","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/cpt.2883","volume":"113","author":"NM Gatto","year":"2023","unstructured":"Gatto NM, Vititoe SE, Rubinstein E, et al. A structured process to identify fit-for-purpose study design and data to generate valid and transparent real-world evidence for regulatory uses. Clin Pharmacol Ther. 2023;113(6):1235\u20139. https:\/\/doi.org\/10.1002\/cpt.2883.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR35","unstructured":"United States Food and Drug Administration (FDA). Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products. Draft guidance for industry. United States Food and Drug Administration (FDA); 2021 [cited 2022 Feb 11]. https:\/\/www.fda.gov\/media\/154714\/download"},{"issue":"384","key":"748_CR36","doi-asserted-by":"publisher","first-page":"e076460","DOI":"10.1136\/bmj-2023-076460","volume":"12","author":"RJ Desai","year":"2024","unstructured":"Desai RJ, Wang SV, Sreedhara SK, Zabotka L, Khosrow-Khavar F, Nelson JC, Shi X, Toh S, Wyss R, Patorno E, Dutcher S, Li J, Lee H, Ball R, Dal Pan G, Segal JB, Suissa S, Rothman KJ, Greenland S, Hern\u00e1n MA, Heagerty PJ, Schneeweiss S. Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA sentinel innovation center. BMJ. 2024;12(384):e076460. https:\/\/doi.org\/10.1136\/bmj-2023-076460.","journal-title":"BMJ"},{"issue":"6","key":"748_CR37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","volume":"170","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss S, Rassen JA, Brown JS, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398\u2013406.","journal-title":"Ann Intern Med"},{"issue":"3","key":"748_CR38","doi-asserted-by":"publisher","first-page":"e0248128","DOI":"10.1371\/journal.pone.0248128","volume":"16","author":"M Stewart","year":"2021","unstructured":"Stewart M, Rodriguez-Watson C, Albayrak A, et al. COVID-19 evidence accelerator: a parallel analysis to describe the use of hydroxychloroquine with or without azithromycin among hospitalized COVID-19 patients. PLoS ONE. 2021;16(3):e0248128.","journal-title":"PLoS ONE"},{"issue":"1","key":"748_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/pds.5507","volume":"32","author":"SV Wang","year":"2023","unstructured":"Wang SV, Potteg\u00e5rd A, Crown W, Arlett P, Ashcroft DM, Benchimol EI, Berger ML, Crane G, Goettsch W, Hua W, Kabadi S, Kern DM, Kurz X, Langan S, Nonaka T, Orsini L, Perez-Gutthann S, Pinheiro S, Pratt N, Schneeweiss S, Toussi M, Williams RJ. HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force. Pharmacoepidemiol Drug Saf. 2023;32(1):44\u201355. https:\/\/doi.org\/10.1002\/pds.5507.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"15","key":"748_CR40","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMp2113319","volume":"385","author":"MA Hern\u00e1n","year":"2021","unstructured":"Hern\u00e1n MA. Methods of public health research \u2014 strengthening causal inference from observational data. N Engl J Med. 2021;385(15):1345\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"748_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/pds.5518","volume":"31","author":"EM Garry","year":"2022","unstructured":"Garry EM, Easthausen IJ, Vititoe SE, Weckstein A, Chakravarty A, Lasky T, Bradley MC, Perez-Vilar S, Rivera DR, Quinto K, Di Z, Zhao Y, Rajpal A, Baglivo A, Rassen JA, Leonard S, Gatto NM. Estimating real-world outcomes under a rapidly evolving treatment paradigm: dexamethasone and inpatient mortality among US hospitalized COVID-19 patients. Pharmacoepidemiol Drug Saf. 2022;31(2):24\u20135. https:\/\/doi.org\/10.1002\/pds.5518.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"748_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1740774511420743","volume":"9","author":"MA Hern\u00e1n","year":"2012","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9(1):48\u201355.","journal-title":"Clin Trials"},{"issue":"6","key":"748_CR43","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","volume":"19","author":"MA Hern\u00e1n","year":"2008","unstructured":"Hern\u00e1n MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766.","journal-title":"Epidemiology"},{"key":"748_CR44","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05638932"},{"key":"748_CR45","unstructured":"Weckstein A, Frajzyngier V, Vititoe SE, Baglivo A, Beebe E, Govil P, Bradley MC, Perez-Vilar S, Liu W, Rivera DR, Chakravarty A, Lasky R, Garry EM, Gatto NM. Adaptive approaches for observational studies: methods for pre-specifying phased diagnostics and contingencies. 40th International Conference for Pharmacoepidemiology, Berlin. Podium, August 2024."},{"issue":"7","key":"748_CR46","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1158\/1055-9965.EPI-20-0606","volume":"29","author":"AT Chan","year":"2020","unstructured":"Chan AT, Drew DA, Nguyen LH, et al. The coronavirus pandemic epidemiology (COPE) consortium: a call to action. Cancer Epidemiol Biomark Prev. 2020;29(7):1283\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"8","key":"748_CR47","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/pds.5029","volume":"29","author":"A Potteg\u00e5rd","year":"2020","unstructured":"Potteg\u00e5rd A, Kurz X, Moore N, et al. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiol Drug Saf. 2020;29(8):825\u201331.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"748_CR48","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/aje\/kwab028","volume":"190","author":"C Renoux","year":"2021","unstructured":"Renoux C, Azoulay L, Suissa S. Biases in evaluating the safety and effectiveness of drugs for the treatment of COVID-19: designing real-world evidence studies. Am J Epidemiol. 2021;190(8):1452\u20136.","journal-title":"Am J Epidemiol"}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00748-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:51:32Z","timestamp":1745434292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00748-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00748-4","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"type":"print","value":"2168-4790"},{"type":"electronic","value":"2168-4804"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper reflects the views of the authors and should not be construed to represent FDA views or policies. Dr. Gatto, Dr. Garry and Ms. Wang are employees of Aetion, Inc., with stock options. During the design, analysis, and interpretation of the research project, Ms. Roe and Ms. Zariffa were affiliated with the U.S. Food and Drug Administration. All other authors declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}